NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells

Molecular Cancer Research

Volumn 11, Issue 4, 2013, Pages 360-369

  Garipov, Azat ^a,d   Li, Hua ^a   Bitler, Benjamin G ^a   Thapa, Roshan J ^b   Balachandran, Siddharth ^b   Zhang, Rugang ^a,c  

^a WISTAR INSTITUTE   (United States)

^b Immune Cell Development and Host Defense Program   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CCAAT BINDING FACTOR; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; PROTEIN P85; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NF YA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER MORTALITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; CCAAT-BINDING FACTOR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84876518140     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0661     Document Type: Article

References (36)

1. American Cancer Society. Cancer facts & figures 2012. Atlanta, GA: American Cancer Society. 2012.
2. Arulkumaran S, Regan L, Farquharson DIM. Obstetrics and gynaecology. Oxford, UK: Oxford University Press; 2011.
3. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8. (Pubitemid 38529752)
4. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43. (Pubitemid 35247314)
5. Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010;8:1610-8.
6. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35. (Pubitemid 37279943)
7. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
8. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999;239:15-27. (Pubitemid 29462565)
9. Marziali G, Perrotti E, Ilari R, Coccia EM, Mantovani R, Testa U, et al. The activity of the CCAAT-box binding factor NF-Y is modulated through the regulated expression of its A subunit during monocyte to macrophage differentiation: regulation of tissue-specific genes through a ubiquitous transcription factor. Blood 1999;93:519-26. (Pubitemid 29035733)
10. Farina A, Manni I, Fontemaggi G, Tiainen M, Cenciarelli C, Bellorini M, et al. Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene 1999;18:2818-27. (Pubitemid 29250871)
11. Bolognese F, Wasner M, Dohna CL, Gurtner A, Ronchi A, Muller H, et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 1999;18: 1845-53. (Pubitemid 29145852)
12. Li XY, Hooft van Huijsduijnen R, Mantovani R, Benoist C, Mathis D. Intron-exon organization of the NF-Y genes. Tissue-specific splicing modifies an activation domain. J Biol Chem 1992;267:8984-90.
13. Gurtner A, Fuschi P, Magi F, Colussi C, Gaetano C, Dobbelstein M, et al. NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PloS ONE 2008;3:e2047.
14. Li Q, Herrler M, Landsberger N, Kaludov N, Ogryzko VV, Nakatani Y, et al. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J 1998;17:6300-15. (Pubitemid 28497802)
15. Yamanaka K, Mizuarai S, Eguchi T, Itadani H, Hirai H, Kotani H. Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics 2009;94:219-27.
16. Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011;30:4118-28.
17. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 1998;26:1135-43. (Pubitemid 28291681)
18. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63. (Pubitemid 38428686)
19. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18: 185-97.
20. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009;16:521-32.
21. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
22. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26: 5284-93.
23. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008;14:4067-78.
24. Hughes R, Kristiansen M, Lassot I, Desagher S, Mantovani R, Ham J. NF-Y is essential for expression of the proapoptotic bim gene in sympathetic neurons. Cell Death Differ 2011;18:937-47.
25. Salsi V, Caretti G, Wasner M, Reinhard W, Haugwitz U, Engeland K, et al. Interactions between p300 and multiple NF-Y trimers govern cyclin B2 promoter function. J Biol Chem 2003;278:6642-50. (Pubitemid 36800650)
26. Kramer A, Carstens CP, Wasserman WW, Fahl WE. CBP/cycA, a CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription, consists of NF-Y and a novel Mr 115, 000 subunit. Cancer Res 1997;57:5117-21. (Pubitemid 27498129)
27. Kramer A, Carstens CP, Fahl WE. A novel CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription at the G1/S boundary is sequestered by a retinoblastoma-like protein in G0. J Biol Chem 1996;271:6579-82. (Pubitemid 26104081)
28. Testa A, Donati G, Yan P, Romani F, Huang TH, Vigano MA, et al. Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J Biol Chem 2005;280:13606-15. (Pubitemid 40517254)
29. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10:191-202. (Pubitemid 44311070)
30. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J Biol Chem 2003;278:30435-40. (Pubitemid 36994546)
31. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J 2006;273:3121-35.
32. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 2012;10:462-72.
33. Gurtner A, Fuschi P, Martelli F, Manni I, Artuso S, Simonte G, et al. Transcription factor NF-Y induces apoptosis in cells expressing wildtype p53 through E2F1 upregulation and p53 activation. Cancer Res 2010;70:9711-20.
34. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C. A balance between NF-Y and p53 governs the pro-and anti-apoptotic transcriptional response. Nucleic Acids Res 2008;36: 1415-28. (Pubitemid 351426096)
35. Kotecha M, Kluza J, Wells G, O'Hare CC, Forni C, Mantovani R, et al. Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78. Mol Cancer Ther 2008;7:1319-28.
36. Hu Q, Bhattacharya C, Maity SN. CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase IIalpha. Conventional CBF activation domains are not required. J Biol Chem 2002;277: 37191-200.